Blueshift Asset Management, LLC Incyte Corp Transaction History

Blueshift Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$63.34 - $74.11 $523,378 - $612,370	-8,263 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $382,011 - $467,403	5,563 Added 206.04%	8,263 $568,000
Q2 2021 Aug 13, 2021	SELL	$79.87 - $87.53 $458,933 - $502,947	-5,746 Reduced 68.03%	2,700 $227,000
Q1 2021 May 06, 2021	BUY	$76.02 - $100.5 $642,064 - $848,823	8,446 New	8,446 $686,000
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $384,968 - $465,833	-4,768 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $405,613 - $523,001	4,768 New	4,768 $428,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.